



RECEIVED  
DEC 19 2003  
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
BEFORE THE BOARD OF PATENT APPEALS AND INTERFERENCES

<i>In re</i> Application of	)	
	)	Group Art Unit: 1631
Williams <i>et al.</i>	)	
	)	Examiner: John S. Brusca
Serial No. 09/297,648	)	
	)	Atty. Docket No. 2300-1481
Filed: March 10, 2000	)	PP-1481-002

For: **HUMAN GENES AND GENE EXPRESSION PRODUCTS II**

**BRIEF ON APPEAL**

James S. Keddle  
Reg. No. 48,920

Carol L. Francis  
Reg. No. 36,513

BOZICEVIC, FIELD & FRANCIS, LLP  
200 Middlefield Rd., Suite 200  
Menlo Park, CA 94025

12/17/2003 HDEMESS1 00000050 500815 09297648  
02 FC:1402 330.00 DA

## TABLE OF CONTENTS

TABLE OF AUTHORITIES	ii
REAL PARTIES IN INTEREST	6
RELATED APPEALS AND INTERFERENCES	6
RELATED PATENTS AND PATENT APPLICATIONS	6
STATUS OF CLAIMS	6
STATUS OF AMENDMENTS	6
SUMMARY OF THE INVENTION	7
ISSUES	7
GROUPING OF CLAIMS	8
SUMMARY OF ARGUMENT	8
ARGUMENT	10
I. The 1952 Patent Act Does Not Provide a Test for Written Description Apart from Enablement and/or the Heightened Tests Set Forth in <i>Lilly</i> .	
II. The '648 Specification Contains a Written Description of the Invention According to 35 U.S.C. § 112, ¶1.	
A. The Legal Standards for Written Description	
B. Grouping of Claims	
C. Appellants Have Provided Overwhelming and Unrebutted Factual Evidence for the Conclusion That Claims 146-154 Meet the Written Description Requirement	
D. The Unrebutted Facts and the Law Mandate Reversal of the Rejection Of Claims 146-154 Based On The Written Description Requirement	
E. Conclusion	

## TABLE OF AUTHORITIES

### Cases

*All Dental Prodx, LLC v. Advantage Dental Products, Inc.*  
2002 U.S. App. LEXIS 22372 (Fed. Cir. October 25, 2002)

*Amgen, Inc. v. Chugai Pharmaceutical Co.,*  
927 F.2d 1200, 18 U.S.P.Q.2d (BNA) 1016 (Fed. Cir. 1991)

*Amgen, Inc. v. Hoechst Marion Roussel, Inc.*  
314 F.3d 1313, 2003 U.S. App. LEXIS 118, 65 U.S.P.Q.2d (BNA) 1385 (Fed. Cir. 2003)

*Application of Lundberg,*  
244 F.2d 543, 113 U.S.P.Q. (BNA) 530 (C.C.P.A. 1957)

*Crown Operations International, Ltd. v. Solutia Inc.,*  
289 F.3d 1367, 62 U.S.P.Q.2d (BNA) 1917 (Fed. Cir. 2002)

*Engel Indus., Inc. v. Lockformer Co.,*  
946 F.2d 1528, 1531, 20 U.S.P.Q.2d (BNA) 1300, 1302 (Fed. Cir. 1991)

*Enzo Biochem, Inc. v. Gen-Probe Inc.,*  
296 F.3d 1316, 63 U.S.P.Q.2d (BNA) 1609 (Fed. Cir. 2002)

*Fiddes v. Baird*  
30 U.S.P.Q.2d (BNA) 1481 (Pat. App. & Interferences Oct. 27, 1993).

*Fiers v. Sugano,*  
984 F.2d 1164, 25 U.S.P.Q.2d (BNA) 1601 (Fed. Cir. 1993)

*In re Alton,*  
76 F.3d 1168, 37 U.S.P.Q.2d (BNA) 1578, 1583 (Fed. Cir. 1996)

*In re Angstadt,*  
537 F.2d 498, 190 U.S.P.Q. (BNA) 214 (C.C.P.A. 1976)

*In re Di Leone,*  
436 F.2d 1404, 168 U.S.P.Q. (BNA) 592 (C.C.P.A. 1971)

*In re Hogan and Banks,*  
559 F.2d 595, 194 U.S.P.Q. (BNA) 527 (C.C.P.A. 1977)

*In re Sus and Schaefer,*  
306 F.2d 494, 134 U.S.P.Q. (BNA) 301 (C.C.P.A., 1962)

*In re Wright*,  
866 F.2d 422, 9 U.S.P.Q.2d (BNA) 1649, 1651 (Fed. Cir. 1989)

*Moba v. Diamond Automation*,  
2003 U.S. App. LEXIS 6285 (Fed. Cir. 2003)

*Phillips Petroleum v. U.S. Steel Corp.*,  
673 F. Supp. 1278, 6 U.S.P.Q.2d (BNA) 1065 (D. Del. 1987)

*Oka v. Youssefyeh*,  
849 F.2d 581, 583 (Fed. Cir. 1988)

*Ralston Purina Co. v. Far-Mar-Co, Inc.*,  
772 F.2d 1570, 227 U.S.P.Q. (BNA) 177 (Fed. Cir. 1985)

*Rexnord Corporation v. Laitram Corporation*,  
274 F.3d 1336, 60 U.S.P.Q.2d (BNA) 1851 (Fed. Cir. 2001)

*United States Steel Corporation v. Phillips Petroleum Company*,  
865 F.2d 1247, 9 U.S.P.Q.2d (BNA) 1461 (Fed. Cir. 1989)

*University of California v. Eli Lilly and Co.*,  
119 F.3d 1559, 43 U.S.P.Q.2d (BNA) 1398 (Fed. Cir. 1997)

*Vas-Cath, Inc. v. Mahurkar*,  
935 F.2d 1555, 19 U.S.P.Q.2d (BNA) 1111 (Fed. Cir. 1991)

#### **Statutes**

35 U.S.C. § 112, ¶1

35 U.S.C. § 132

#### **Regulations**

37 C.F.R. § 1.104(d)(2)

#### **Other**

Agreement on Trade-Related Aspects of Intellectual Property Rights, April 15, 1994, Marrakech Agreement Establishing the World Trade Organization, Annex 1C, Legal Instruments – Results of the Uruguay Round, 33 I.L.M. 81 (1994)

U.S. Patent and Trademark Office Written Description Guidelines,

66 Fed. Reg. 1099 (January 5, 2001)

U.S. Patent and Trademark Office's Synopsis of Application of Written Description Guidelines

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
BEFORE THE BOARD OF PATENT APPEALS AND INTERFERENCES**

<i>In re</i> Application of	)	
	)	Group Art Unit: 1631
Williams <i>et al.</i>	)	
	)	Examiner: John S. Brusca
Serial No. 09/297,648	)	
	)	Atty. Docket No. 2300-1481
Filed: March 10, 2000	)	PP-1481-002

For: **HUMAN GENES AND GENE EXPRESSION PRODUCTS II**

**BRIEF ON APPEAL**

Commissioner of Patents  
Alexandria, V.A. 20231

Sir:

Appellants submit an original and two copies of this brief. Appellants file the Notice of Appeal herewith.

Please charge the \$330.00 fee for filing this Brief, the \$290.00 for the Request for Oral Hearing and the Notice of Appeal fee of \$330.00 to our Deposit Account No. 50-0815, order number 2300-1481. If this fee is incorrect, please charge or credit the account accordingly.

### **REAL PARTIES IN INTEREST**

The real parties in interest in this application are Chiron Corporation and Hyseq Corporation to which this application is assigned. Hyseq Corporation has changed its name to Nuvelo, Inc.

### **RELATED APPEALS AND INTERFERENCES**

There are no related appeals or interferences.

### **RELATED PATENTS AND APPLICATIONS**

The above referenced application is a 35 USC § 371 national phase application of PCT application serial number PCT/US99/01619, filed December 28, 1999, which application claims the benefit of the following provisional patent applications: 60/072,910, filed January 28, 1998, 60/075,954 filed February 24, 1998, 60/080,114 filed March 31, 1998, 60/080,515 filed April 3, 1998, 60/105,234 filed October 21, 1998, 60/105,877 filed October 27, 1998 and 60/080,666 filed April 3, 1998.

### **STATUS OF CLAIMS**

Claims 146-154 stand rejected. Claims 146-154 are appealed.

### **STATUS OF AMENDMENTS**

The last amendment to the claims was filed November 1, 2002. That amendment has been entered.

Appendix I sets forth the currently pending claims.

## **SUMMARY OF THE INVENTION**

All of the claims are based on the inventors' discovery of polynucleotide molecules having at least a 50 contiguous nucleotides of the sequence set forth in SEQ ID NO:253, which polynucleotides may be used to detect nucleic acids that are expressed at higher levels in cancerous cells as compared to non-cancerous cells. The claimed polynucleotides are therefore useful for a wide variety of diagnostic purposes.

Claim 146 is illustrative of the claims on appeal:

146. An isolated polynucleotide comprising at least 50 contiguous nucleotides of a sequence selected from SEQ ID NO:253 and the complement thereof.

Claims 147-154, recite vectors and host cells, polynucleotides that hybridize, polynucleotides deposited with the A.T.C.C. and nucleic acid products made by amplification, that directly or indirectly, recite the defining characteristics of Appellants' invention: a polynucleotide having at least 50 contiguous nucleotides of a sequence selected from SEQ ID NO:253 and the complement thereof.

## **ISSUES**

I. The 1952 Patent Act Does Not Provide a Test for Written Description Apart from Enablement and/or the Heightened Tests Set Forth in *Lilly*.

II. The '648 Specification Contains a Written Description of the Invention According to 35 U.S.C. § 112, ¶1.



## **GROUPING OF CLAIMS**

Claims 147-154 all stand or fall together with respect to issues I.

The following groups of claims stand or fall together with respect to issue II:

Group I:        Claims 146-150 and 152-154

Group II:       Claim 151

## **SUMMARY OF ARGUMENT**

Each of the appealed claims is directed to a genus of polynucleotides molecules that is defined by the required presence of an identifying polynucleotide sequence of at least 50 contiguous nucleotides of a sequence selected from SEQ ID NO:253 or of at least 50 contiguous nucleotides of an insert contained in a vector deposited at the A.T.C.C., and the complements thereof, as discovered by the inventors. The identifying polynucleotide sequence is recited either directly or indirectly in all of the claims. None of the claims requires that the claimed polynucleotide molecules encode a “full-length cDNA”, and none of the claims requires that the claimed polynucleotides encode a particular amino acid sequence.

The utility of the claimed nucleic acids (for example, as cancer diagnostic probes or starting materials for such probes) has not been disputed and has never been challenged.

All of the appealed claims are written in open form. That is, they employ the claim transition phrase “comprising.” Again, claim 146 is illustrative (see Summary of the Invention, *supra*). As such, any of the nucleic acids encompassed by the appealed claims may contain nucleic acid residues flanking the 5' and/or the 3' ends of the recited identifying polynucleotide sequence. The appealed claims do not recite the sequence or function of the flanking nucleic

acids, and do not recite that the flanking nucleic acids encode a portion of a protein. It is this open form of the claims that appears to have given rise to all rejections on appeal.

Each appealed claim stands rejected under 35 U.S.C. § 112, ¶1, assertedly because the specification of the '648 patent application does not adequately describe the claimed invention.

Since the exact nucleotide sequence of SEQ ID NO:253 is provided in the specification of the '648 patent application, the Appellants have repeatedly questioned the support underlying the Office's rejection of the pending claims and have requested an Examiner's affidavit under 37 C.F.R. § 1.104(d)(2). No support, however, has been provided. Instead, the Office has stated that that the appealed claims, because they are written in open form, encompass the full-length cDNA to which SEQ ID NO:253 corresponds, and, because the sequence of that full-length cDNA is not specifically disclosed in the specification, the claims do not meet the written description requirement of 35 U.S.C. § 112, ¶1. In other words, the Examiner has taken the position that unless Appellants disclose the polynucleotide sequence of a single species, i.e., the "full-length cDNA", the specification fails to meet the written description requirement of 35 U.S.C. §112, ¶1.

Appellants agree that a full-length cDNA having the sequence of SEQ ID NO:253 is encompassed by the appealed claims. There is, however no limitation in any of the claims that requires that the claimed polynucleotides be the full length cDNA. In other words, while the full-length cDNA to which SEQ ID NO:253 corresponds is encompassed by the claims, the claims are not so limited to such cDNAs. Rather, the full-length cDNA is but one species of the polynucleotides encompassed by the claimed genus. Since there is no requirement that every species of a claimed genus be specifically described in a patent specification in order to satisfy 35 U.S.C. §112, ¶1, there is no basis for this rejection.

Moreover, because there is no indication in the record that the full-length cDNA to which SEQ ID NO:253 was known in the art when the '648 specification was filed, the full-length cDNA to which SEQ ID NO:253 corresponds constitutes a later-discovered species within Appellants' generic claims. The fact that Appellants' generic claims encompass a species which is not recited in the claims is irrelevant as to whether Appellants are entitled to the appealed claims. What is relevant is whether the appealed generic claims, as properly interpreted, meet the statutory requirements for written description under 35 U.S.C. § 112, ¶1. Appellants believe that all the claims meet these statutory requirements and that the rejections are based on an improper application of the law and should be withdrawn.

## **ARGUMENT**

### **I. The 1952 Patent Act Does Not Provide a Test for Written Description Apart From Enablement and/or the Heightened Tests Set Forth in *Lilly***

The rejection for failure to comply with the written description requirement should be reversed because the 1952 Patent Act does not contain a separate written description requirement apart from enablement under 35 U.S.C. § 112, ¶1 and the prohibition against new matter under 35 U.S.C. § 132. Furthermore, even if there is a separate written description requirement in § 112, ¶1, the elevation of that test beyond the requirements of enablement and the prohibition against new matter is contrary to binding precedent of the Court of Customs and Patent Appeals (C.C.P.A.) and the Court of Appeals of the Federal Circuit. *See, e.g., Enzo Biochem. Inc. v. Gen-Probe Inc.*, 63 U.S.P.Q.2d (BNA) 1609, 1622 (Fed. Cir. 2002) (Rader, J. dissenting). A later three-judge panel cannot overturn prior precedential decisions of the C.C.P.A. and the Court of Appeals of the Federal Circuit. *Enzo Biochem. Inc. v. Gen-Probe Inc.*, 63 U.S.P.Q.2d (BNA) 1609, 1628; *Vas-Cath, Inc. v. Mahurkar*, 935 F.2d 1555, 1563, 19 U.S.P.Q.2d (BNA) 1111, 1117

(Fed. Cir. 1991). Thus, because *University of California v. Eli Lilly and Co.*, 119 F.3d 1559, 43 U.S.P.Q.2d 1398 (Fed. Cir. 1997), purports to change or elevate the written description requirement inconsistent with prior binding precedent and beyond the requirements of enablement under § 112, ¶1 and the prohibition against new matter under § 132, the Office should not apply it in the examination of applications. In other words, because the rejection of claims 146-154 was primarily based on *Lilly*, the rejection should be reversed.

Appellants note that the discussions of *Lilly* in *Amgen Inc. v. Hoechst Marion Roussel, Inc.*, 314 F.3d 1313, 2003 U.S. App. LEXIS 118, 65 U.S.P.Q.2D (BNA) 1385 (Fed. Cir. 2003) and in *Moba v. Diamond Automation*, 2003 U.S. App. LEXIS 6285 (Fed. Cir. 2003), indicate that the application of the tests for written description as set out in *Lilly* is currently in question. Appellants appreciate that the Board may feel that this issue should be left to the Federal Circuit to review. Nevertheless, Appellants want to provide the Board with an opportunity to express its views for the benefit of further review, as well as to preserve the issue for appeal.

## **II. The Specification Contains a Written Description of the Invention According to 35 U.S.C. § 112, ¶1**

Whether a patent specification meets the written description requirement for a claimed invention is a question of fact. *Vas-Cath*, 935 F.2d 1555, 1563, 19 U.S.P.Q.2d (BNA) 1111, 1116. In arguing that they have met the written description requirement, Appellants have provided the U.S. Patent and Trademark Office with an extensive factual record. That record, which includes the expert declaration of Dr. Christopher R. Somerville, filed November 1, 2002, establishes beyond doubt that all the appealed claims meet the written description requirement of 35 U.S.C. § 112, ¶1. The Office has improperly ignored and discounted Appellants' factual showing and has instead made unsupported assertions in making the rejection. Appellants have

repeatedly questioned the support underlying the Examiner's rejection and have requested an Examiner's affidavit under 37 C.F.R. § 1.104(d)(2). No such support, however, has been provided. Thus, there is no evidentiary basis for the Examiner's alleged factual finding. In addition, the Examiner has misstated and misapplied the law on written description. The rejection should be reversed.

A. The Legal Standards for Written Description

The rejection is based on an allegation that because the claims are written in open form using the transitional phrase "comprising", the scope of the written description provided by the specification is insufficient to support the claims.

The first paragraph of 35 U.S.C. § 112 requires that the specification provide a written description of the claimed invention:

[t]he specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.

The purpose of the written description requirement is to ensure that the specification conveys to those skilled in the art that the applicants possessed the claimed subject matter as of the filing date sought. *Vas-Cath Inc. v. Mahurkar*, 935 F.2d 1555, 1563-64, 19 U.S.P.Q.2d (BNA) 1111, 1117 (Fed. Cir. 1991). *See also All Dental Prodx, LLC v. Advantage Dental Products, Inc.*, 2002 U.S. App. LEXIS 22372, \*10-11 (Fed. Cir. 2002) ("the specification must simply indicate to persons skilled in the art that as of the [filing] date the applicant had invented what is now claimed."). Thus, the test for whether a claimed invention is adequately described has often been stated as whether or not one of skill in the art would have understood from the specification that an applicant possessed the claimed subject matter when the specification was filed. *See, e.g.*,

*Ralston Purina Co. v. Far-Mar-Co*, 772 F.2d 1570, 1575, 227 U.S.P.Q. (BNA) 177, 179 (Fed. Cir. 1985). Whether the specification meets the written description requirement for the claimed invention is a question of fact. *Vas-Cath*, 935 F.2d 1555, 1563, 19 U.S.P.Q.2d (BNA) 1111, 1116.

The specification must be considered as a whole when determining whether the written description requirement is met. *In re Wright*, 866 F.2d 422, 425, 9 U.S.P.Q.2d (BNA) 1649, 1651 (Fed. Cir. 1989). Compliance with the written description requirement must be assessed on a case-by-case basis. *Crown Operations International, Ltd. v. Solutia Inc.*, 289 F.3d 1367, 1376, 62 U.S.P.Q.2d (BNA) 1917, 1922 (Fed. Cir. 2002).

What is required to satisfy the written description requirement depends on the nature of the invention claimed. *In re Di Leone*, 436 F.2d 1404, 1405, 168 U.S.P.Q. (BNA) 592, 593 (C.C.P.A. 1971). According to *Enzo Biochem, Inc. v. Gen-Probe Incorporated*, 296 F.3d 1316, 63 U.S.P.Q.2d (BNA) 1609 (Fed. Cir. 2002), “the language of the specification, to the extent possible, must describe the claimed invention so that one skilled in the art can recognize what is claimed.” 296 F.3d 1316, 1326, 63 U.S.P.Q.2d (BNA) 1609, 1615. Specifically discussing nucleic acid molecules, the *Enzo* court recently approved two means by which the written description requirement can be met. First, “reference in the specification to a deposit in a public depository, which makes its contents accessible to the public when it is not otherwise available in written form, constitutes an adequate description of the deposited material sufficient to comply with the written description requirement of § 112, ¶ 1.” 296 F.3d 1316, 1325, 63 U.S.P.Q.2d (BNA) 1609, 1613. Second, the written description requirement can be met by “show[ing] that an invention is complete by disclosure of sufficiently detailed, relevant identifying characteristics . . . i.e., complete or partial structure, other physical and/or chemical properties, functional

characteristics when coupled with a known or disclosed correlation between function and structure, or some combination of such characteristics.” Written Description Guidelines, 66 Fed. Reg. 1099, 1106 (January 5, 2001); approved in *Enzo*, 296 F.3d 1316, 1325, 63 U.S.P.Q.2d (BNA) 1609, 1613.

The Court of Appeals for the Federal Circuit also has stated that written description of a genus of polynucleotide molecules may be achieved by sufficiently describing a representative number of species within the genus:

A description of a genus of cDNAs may be achieved by means of a recitation of a representative number of cDNAs, defined by nucleotide sequence, falling within the scope of the genus or of a recitation of structural features common to the members of the genus, which features constitute a substantial portion of the genus. This is analogous to enablement of a genus under § 112, ¶ 1, by showing the enablement of a representative number of species within the genus.

*University of California v. Eli Lilly and Co.*, 119 F.3d 1559, 1569, 43 U.S.P.Q.2d (BNA) 1398, 1406 (Fed. Cir. 1997) (footnotes and internal references omitted). As long as the specification permits one of skill in the art to “visualize or recognize the identity of members of the genus,” the genus is adequately described. 119 F.3d 1559, 1568, 43 U.S.P.Q.2d (BNA) at 1406. The options set forth in *Lilly* for describing a genus of polynucleotide molecules are reflected in the U.S. Patent and Trademark Office’s Written Description Guidelines:

The written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice, reduction to drawings, or by disclosure of relevant, identifying characteristics, *i.e.*, structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics . . . .

66 Fed. Reg. at 1106. As noted above, the Court of Appeals for the Federal Circuit has specifically approved this option for satisfaction of the written description requirement. *Enzo*, 296 F.3d at 1325, 63 U.S.P.Q.2d (BNA) 1613.

However, it is also noted that Lilly fails as a test for adequate written description in several cases, e.g., *Amgen Inc. v. Hoechst Marion Roussel, Inc.* 314 F.3d 1313, 2003 U.S. App. LEXIS 118, 42, 65 U.S.P.Q.2D (BNA) 1385 (Fed. Cir. 2003) (stating that “Both Eli Lilly and Enzo Biochem are inapposite to this case because the claim terms at issue here are not new or unknown biological materials that ordinarily skilled artisans would easily miscomprehend.”). In particular, the Federal Circuit in *Moba v. Diamond Automation, Inc.*, 2003 U.S. App. LEXIS 6285, 33 (Fed. Cir. 2003) stated: “the Lilly disclosure rule does not require a particular form of disclosure because one of skill could determine from the specification that the inventor possessed the invention at the time of filing”. Despite the uncertainty in the law regarding the application of the structural test set forth in *Lilly*, it is this test that nonetheless forms the primary basis for this rejection.

Structural tests for adequate written description of a DNA invention that are similar to the test provided by *Lilly* are also provided in *Fiddes v. Baird* 30 U.S.P.Q.2d 1481, 1398 (BPAI 1993):

An adequate description of a DNA requires more than a mere statement that it is part of the invention and reference to a potential method for isolating it; what is required is a description of the DNA itself.

\* \* \*

If a conception of a DNA requires a specific definition, such as by structure, formula, chemical name, or physical properties, as we have held, then a description also requires that degree of specificity....[O]ne cannot describe what one has not conceived. (*Id.* at 1482-83, citing *Fiers*, 984 F.2d at 1170-71.)



and in *Amgen, Inc. v. Chugai Pharmaceutical, Co.*, 927 F.2d 1200, 18 U.S.P.Q.2d (BNA) 1016 (Fed. Cir. 1991). The *Amgen* court stated:

A gene is a chemical compound, albeit a complex one, and it is well established in our law that conception of a chemical compound requires that the inventor be able to define it so as to distinguish it from other materials, and to describe how to obtain it. Conception does not occur unless one has a mental picture of the structure of the chemical, or is able to define it by its method of preparation, its physical or chemical properties, or whatever characteristics sufficiently distinguish it. (*Amgen*, 927 F.2d at 1206, citations omitted)

As such, *Amgen* provides a test for adequate written description that involves allowing sufficiently distinguishing a claimed compound from other compounds.

Even in an “unpredictable art,” applicants “are *not* required to disclose *every* species encompassed by their claims . . . .” *In re Angstadt*, 537 F.2d 498, 502-03, 190 U.S.P.Q. (BNA) 214, 218, (C.C.P.A. 1976). Thus, features that apply to only some species within a generic claim – but not to all species encompassed by the claim – need not be described to satisfy the written description requirement. Otherwise, to claim a genus, every species within a genus would have to be explicitly described. That is not the law. See *Engel Indus., Inc. v. Lockformer Co.*, 946 F.2d 1528, 1531, 20 U.S.P.Q.2d (BNA) 1300, 1302 (Fed. Cir. 1991) (“Unclaimed subject matter is not subject to the disclosure requirements of § 112; the reasons are pragmatic: the disclosure would be boundless, and the pitfalls endless.”). See also *Phillips Petroleum v. U.S. Steel Corp.*, 673 F. Supp. 1278, 1292, 6 U.S.P.Q.2d (BNA) 1065, 1074 (D. Del. 1987) (“The applicant is not required to include in his application support for matters not set forth in the claim.”), *aff’d* 865 F.2d 1247, 9 U.S.P.Q.2d (BNA) 1461 (Fed. Cir. 1989). Description of later-invented species that now fall within a claimed genus certainly is not required. *Rexnord Corporation v. Laitram*

*Corporation*, 274 F.3d 1336, 1344, 60 U.S.P.Q.2d (BNA) 1851, 1856 (Fed. Cir. 2001) (“Our case law is clear that an applicant is not required to describe in the specification every conceivable and possible future embodiment of his invention.”). *See also In re Hogan and Banks*, 559 F.2d 595, 605-06, 194 U.S.P.Q. (BNA) 527, 537 (C.C.P.A. 1977); *United States Steel Corporation v. Phillips Petroleum Company*, 865 F.2d 1247, 1251-52, 9 U.S.P.Q.2d (BNA) 1461, 1465 (Fed. Cir. 1989).

B. Grouping of claims

The claims are grouped as follows:

Group I claims (claims 146-150 and 152-154). The polynucleotides of Group I have a defining feature of a polynucleotide sequence of at least 50 contiguous nucleotides of SEQ ID NO:253, or complement thereof.

Group II claim (claim 151). The polynucleotides of Group II have a defining feature of a polynucleotide sequence of at least 50 contiguous nucleotides of an insert of a vector deposited at the American Type Culture Collection (A.T.C.C.).

C. Appellants Have Provided Overwhelming and Unrebutted Factual Evidence for the Legal Conclusion that the Specification Sufficiently Describes Claims 146-154.

As noted above, the question of whether a patent specification meets the written description requirement for a claimed invention is a question of fact. *Vas-Cath*, 935 F.2d at 1563, 19 U.S.P.Q.2d (BNA) at 1116. In order to answer this question, the Appellants provided during prosecution of this case an expert declaration of Dr. Christopher Somerville and accompanying documentary exhibits filed November 1, 2002 (“SD”). A copy of Dr. Somerville’s declaration is enclosed herewith as Appendix II.

Dr. Somerville is a Director of the Carnegie Institution of Washington Department of Plant Biology, a Professor of the Department of Biological Sciences at Stanford University, an elected member of the U.S. National Academy of Sciences, an elected fellow of the Royal Societies of London and Canada and has served on the editorial boards of several international peer-reviewed journals and several government panels. SD ¶ 3. Dr. Somerville has worked in the field of recombinant DNA technology for over 20 years and has published over 150 articles in the fields of genetics, biochemistry, molecular biology and genomics. SD ¶ 3.

Dr. Somerville understands that the '648 application is to be viewed from the standpoint of one of ordinary skill in the art in the relevant field at the time of filing of the application (referred to by Dr. Somerville and by the Appellants as a "Skilled Person"). SD ¶ 7. Dr. Somerville believes that he is qualified by training and experience to address what a Skilled Person would have understood from a reading of the specification of U.S. Patent Application No. 09/297,648 as of its filing date on March 10, 2000. SD ¶ 9

Dr. Somerville has reviewed the above referenced patent application and the Office Action, SD ¶ 4. Dr. Somerville understands that the polynucleotides encompassed by each of the claims are a genus of polynucleotides characterized as having the common structural feature of a nucleotide sequence containing a minimum of 50 contiguous nucleotides of SEQ ID NO:253 or at least 50 contiguous nucleotides of an insert of a vector deposited with the A.T.C.C.. SD ¶ 5. Dr. Somerville also understands that the word "comprising" as used in the appealed claims means that flanking sequences can be present in addition to a recited sequence. SD ¶ 12.

Dr. Somerville stated that it is his unequivocal opinion that a Skilled Person would conclude from a review of the '648 application as a whole, that the Inventions (i.e., the subject matter defined by claims 146-154) were described in the '648 application and in the inventors'

possession, and further that the disclosure of '648 application contains representative examples of the Inventions. SD ¶ 8.

When read in conjunction with the '648 specification, it is Dr. Somerville's unequivocal opinion that, a Skilled Person would find that the '648 specification describes polynucleotides fully representative of the genus of polynucleotides of the Invention since:

a) the Skilled Person would recognize disclosure of SEQ ID NO:253 as fully representative of the genus of the Invention since it is a complete disclosure of the common structural feature (i.e., at least 50 contiguous nucleotides of SEQ ID NO:253) of the Inventions; and

b) the Skilled Person would recognize the vector containing a cDNA containing the sequence of SEQ ID NO:253 and deposited with the A.T.C.C. is an example of a polynucleotide containing SEQ ID NO:253 having flanking sequences and as being fully representative of large polynucleotides that can serve as probes or starting materials for probes in cancer diagnostics. SD ¶ 18.

The bases for this conclusion are set forth below.

1. Skilled person

A Skilled Person in the field of recombinant DNA technology in March 2000 is represented by a scientist with a Ph.D. degree and two years of post-doctoral training. SD ¶ 7. A Skilled Person would have the ability to analyze a DNA sequence using the common general knowledge, tools, and methods available in the field and without inventive effort. *Id.* Furthermore, such a Skilled Person would have had access to and would have used as needed persons of ordinary skill in other technical fields, such as (by way of illustration and not limitation) cellular biology, oncology, biochemistry, immunology, physiology and diagnostics. *Id.*

In March 2000, the common general knowledge, tools, and well-known methods available in this field were extensive. SD ¶ 8. Widely available methods included nucleotide hybridization, nucleic acid cloning, polymerase chain reaction (PCR), reverse transcriptase PCR (RT-PCR), gene sequencing and cDNA library construction and screening. *Id.* In addition, several “bioinformatics” tools were available, such as bioinformatics programs for searching a database of nucleic acids sequences for similar nucleic acid sequences (e.g. BLAST), programs for comparing two nucleic acid sequence (e.g. the BESTFIT or GAP programs as provided by the University of Wisconsin’s GCG program) and programs for predicting and annotating coding sequences of genes (e.g. GENSCAN and XGRAIL). *Id.*

2. Polynucleotide molecules claimed in each of claim Groups I and II contain common structural features.

As discussed above, the polynucleotide molecules encompassed by Group I claims contain a common structural feature that is a sequence of at least 50 contiguous nucleotides of SEQ ID NO:253, or complement thereof. The polynucleotides of the claim of Group II have a common structural feature that is a sequence of at least 50 contiguous nucleotides of an insert of a vector deposited at the A.T.C.C.

3. The ‘648 specification explicitly describes the common structural feature that the polynucleotide molecules of Group I must contain.

The sequence of SEQ ID NO:253 is provided in the sequence listing of the ‘648 application. SD ¶ 11. As recited in the sequence listing, SEQ ID NO:253 is provided as follows:

```

<400> 253
gaacaaagaa ggaatgtctt cctcatgttt gggctctatag aagacgttaa agaaaacttc 60
aagaaagtgg gtttgaggca tgagccacca cgctggcca aaggatttaa tgaattaatg 120
gatgtacagt gctggggctg ttattctagg gcctgcattg agactcacat ttgccatca 180
aaagcctttt aagaggtgga ggttgcggtg agctgacatg gtgccactgc actccggcct 240
gagtgacaga gtgagactct gtctcacaaa aaaaataatg ccctttaaat aatgaataat 300

```

Description of polynucleotide molecules containing at least 50 contiguous nucleotides of SEQ ID NO:253 is found on page 9, lines 6-10 of the '648 specification. SD ¶ 11.

Further, the sequence set forth in SEQ ID NO:253 was obtained a plasmid contained in clone number M00001448D:C09, SD ¶ 11, and this clone was deposited with the A.T.C.C.

A Skilled Person, taking these disclosures together, would find specific description in the '648 application of the recited common structural feature for Group I claims: the sequence of at least 50 contiguous nucleotides of SEQ ID NO:253. SD ¶ 11.

4. The '648 specification describes a vast number of polynucleotide molecules that are larger than the common structural feature and contain the common structural feature.

The '648 specification describes nucleic acid probes containing the common structural feature that are often longer than 50 contiguous polynucleotides in length. '648 specification page 9 lines 15-22, page 10 lines 12-19, SD ¶ 13. Sambrook *et al.*, incorporated by reference into the '648 specification, also describes several types of probes that contain flanking sequences, including hybridization probes, oligonucleotide probes, RNA probes, plasmid probes and polymerase chain reaction probes. SD ¶ 13. For example, a skilled person would recognize that a probe may contain polylinker sequences, or an oligonucleotide "tail". SD ¶ 13.

Polynucleotide vectors containing the common structural feature, which a Skilled Person would recognize as always being longer than the common structural feature, are described in several positions of the specification. '648 specification page 10 lines 3-6, page 15 lines 5-12, page 16 lines 16-23, page 74 line 13-page 75 line 19, SD ¶ 14.

The '648 specification also describes cDNA and gene polynucleotide molecules containing the common structural feature, one of which was deposited at the A.T.C.C. '648 specification page 8 lines 16-21, '648 specification page 8 lines 13-page 9 line 2, and SD ¶ 15, SD ¶ 16.

The '648 specification specifically describes a wide variety of polynucleotide molecules containing at least 50 contiguous nucleotides of SEQ ID NO:253 along with flanking sequences, e.g. probes, vectors, cDNAs, clones, full length cDNAs, genes etc. SD ¶ 17. As such, the '648 specification describes large polynucleotides containing fragments of SEQ ID NO:253. The vector containing a cDNA containing the sequence of SEQ ID NO:253 and deposited with the A.T.C.C. is an example of a polynucleotide containing SEQ ID NO:253 and having such flanking sequences. *Id.* The overall disclosure of the specification demonstrates that there is no criticality to sequences flanking the polynucleotides of the Invention. *Id.* Rather, selection of such flanking sequences is an arbitrary matter of design. *Id.* The Skilled Person would readily appreciate from the specification that the sequence of SEQ ID NO:253 can be incorporated within a vast number of larger polynucleotide molecules, and that each of these sequences is identifiable as having at least 50 contiguous nucleotides of SEQ ID NO:253. Each of these polynucleotide molecules is, for example, useful as a probe or a starting material for a probe (see, e.g., page 5, lines 7-14 of the '648 specification). SD ¶ 17.

5. A vector that is fully representative of the claimed polynucleotide molecules was deposited with the A.T.C.C. prior to the filing date of the '648 patent application.

Table 1 of the '648 application describes biological deposits which include vectors containing an insert, which insert contains the sequences described in the application. Table 1 indicates that a clone encompassing the sequence of SEQ ID NO:253 is deposited as clone M00001448D:C09 at the A.T.C.C.. SD ¶ 29. This deposit was made before the filing date of this application.

The Skilled Person would recognize the vector containing a cDNA containing the sequence of SEQ ID NO:253 and deposited with the A.T.C.C. is an example of a polynucleotide containing SEQ ID NO:253 having flanking sequences and as being fully representative of large polynucleotides that can serve as probes or starting materials for probes in cancer diagnostics. SD ¶ 18.

6. A Skilled Person would recognize the common structural feature and be able to straightforwardly determine whether a given polynucleotide falls within any one of the claims based on the provided structural feature

The Skilled Person would have been able to straightforwardly determine whether a given polynucleotide falls within any one of the claims based on the provided structural characteristics or routine hybridization experiments. SD ¶ 45 Only routine methodologies would be required to determine whether a given polynucleotide would be within a genus of an Invention. *Id.* For example, a Skilled Person, by performing a simple sequence comparison, e.g. a pairwise “BESTFIT” alignment between SEQ ID NO:253 and any given nucleotide would have been able to straightforwardly determine whether a given polynucleotide fell within any one of the claims:



the given polynucleotide either has 50 nucleotides of sequence identity with SEQ ID NO:253 or it does not. SD ¶ 20.

D. The Unrebutted Facts and the Law Mandate Reversal of the Rejection of Claims 146-154 Based on the Written Description Requirement.

1. Properly construed claims 146-154 recite specific sequences but contain no requirement for a full length cDNA.

The first step in a written description inquiry is to properly construe the claims. *Vas-Cath Inc.*, 935 F.2d at 1560, 19 U.S.P.Q.2d (BNA) at 1116.

Group I claims encompass isolated polynucleotide molecules, vectors containing the polynucleotide molecules, and host cells containing the vectors. Each of the claims of Group I recites directly or indirectly, the defining characteristics of Appellants' invention: at least 50 contiguous nucleotides of a sequence selected from SEQ ID NO:253 and the complement thereof

Claim 146 is illustrative of the claims on appeal:

146. An isolated polynucleotide comprising at least 50 contiguous nucleotides of a sequence selected from SEQ ID NO:253 and the complement thereof.

The claim of Group II (Claim 151) encompasses a polynucleotide molecule that recites a defining characteristic of the Appellants' invention: at least 50 contiguous nucleotides of either strand of a nucleotide insert contained in a vector deposited as clone M00001448D:C09 of A.T.C.C. Deposit Number 207068. This insert contains the sequence of SEQ ID NO:253.

For Group I claims, the claimed polynucleotides must include at least 50 contiguous nucleotides of SEQ ID NO:253 or its complement. The subject polynucleotide molecules are claimed using an "open" claim structure and thus may include flanking sequences.

For the Group II claim, the claimed polynucleotides must include at least 50 contiguous nucleotides of an insert of a vector deposited with the A.T.C.C. This insert includes a polynucleotide having the sequence of SEQ ID NO:253. Again, the subject polynucleotide molecules are claimed using an “open” claim structure and thus may include flanking sequences.

The claims do not require any particular flanking sequence. In particular, none of the claims requires that the isolated polynucleotides are full length cDNA, have an open reading frame, or have any particular structure or biological function. The Appellants asserted this during prosecution. See, e.g., Amendment and Response filed November 1, 2002, page 8. The Examiner never disputed Appellants’ assertion or pointed to any claim term that could possibly be read to impose such a requirement. In fact, the Examiner stated that the structure of flanking vector polynucleotide sequences are well known to one of skill in the art. See the Office Action dated January 15, 2003 (paper 32), page 4.

The claimed polynucleotides, including polynucleotides that have flanking sequences, can serve as probes or starting materials for probes in cancer diagnostics SD ¶ 18. As such, every one of the claimed polynucleotides has an acknowledged specific, substantial and credible utility. *Id.* None of these uses requires a claimed polynucleotide be full length cDNA. In fact, none of these uses requires a claimed polynucleotide to contain flanking nucleic acids of any particular sequence. As Dr. Somerville states, the overall disclosure of the specification demonstrates that there is not criticality to sequences flanking the polynucleotides of the Invention. Rather, selection of such flanking sequences is an arbitrary matter of design.

2. The ‘648 specification satisfies the tests for adequate written description under each of Vas-Cath, Lilly, and Enzo.

*Vas-Cath* sets forth a test for whether a specification meets the written description requirement. 935 F.2d at 1563-64, 19 U.S.P.Q.2d at 1117. *Lilly* and *Enzo* set forth means by

which a specification can satisfy the written description requirement for generic claims to nucleic acid molecules in particular. *Lilly*, 119 F.3d at 1569, 43 U.S.P.Q.2d at 1406; *Enzo*, 296 F.3d at 1324, 1325, 63 U.S.P.Q.2d at 1613. The extensive factual record in this application demonstrates without question that the '648 specification satisfies the tests for under each of the rubrics of written description enunciated in *Vas-Cath*, *Lilly*, and *Enzo*, and, as such, provides adequate written description of the subject matter encompassed by each of the appealed claims 146-154.

a. *Vas-Cath*

Under *Vas-Cath*, the '648 specification must convey to one of skill in the art that Appellants possessed the invention to which the appealed claims are directed when that specification was filed. 935 F.2d at 1563-64, 19 U.S.P.Q.2d (BNA) at 1117.

Dr. Somerville, in his declaration, understands that the claimed polynucleotides may contain flanking sequences. For each of the appealed claims, Dr. Somerville establishes beyond doubt that the inventors' disclosure meets the possession test provided by *Vas-Cath*:

Dr. Somerville declares:

Based on the foregoing, it is also my unequivocal opinion that a Skilled Person would find that the '648 specification demonstrates that applicants had possession of the genera of polynucleotides of claims 146-148. SD ¶ 19

It is therefore my unequivocal opinion that a Skilled Person would, in March 2000, have found the specific description of the claimed genus of polynucleotides in the specification to be a sufficient structural description of the claimed Inventions and to demonstrate applicants had possession of the Invention of Claims 149 or 150. SD ¶ 26

Based upon the above disclosures in the '648 application, it is my unequivocal opinion that a Skilled Person would find that the '648 application describes the Invention of Claim 151 and recognize that the inventors were in possession of that Invention. SD ¶ 31

Based upon the above disclosures in the '648 application, it is my unequivocal opinion that a Skilled Person would find that the '648 application describes the Invention of Claims 152-154 and recognize that the inventors were in possession of that Invention.  
SD ¶ 41

Dr. Somerville's Declaration contains a sound basis of this conclusion.

First, Dr. Somerville states that the '648 specification explicitly teaches the common structural feature of each of the claimed genera of nucleic acids, *i.e.*, the polynucleotide sequence of SEQ ID NO:253. SD ¶ 11. Dr. Somerville states that a description of polynucleotides containing at least 50 contiguous nucleotides of SEQ ID NO:253 is found on page 9, lines 6-10 of the '648 specification. SD ¶ 11. Dr. Somerville states that a Skilled Person, taking these disclosures together, would find specific description in the '648 application of the recited common structural feature for Group I claims: the sequence of at least 50 contiguous nucleotides of SEQ ID NO:253. SD ¶ 11.

Dr. Somerville explains how the '648 specification specifically describes a wide variety of polynucleotides containing at least 50 contiguous nucleotides of SEQ ID NO:253 along with flanking sequences, e.g. probes, vectors, cDNAs, clones, full length cDNAs, genes etc. SD ¶ 17.

Furthermore, an actual clone encompassing the sequence of SEQ ID NO:253 was deposited with the A.T.C.C. as clone number M00001448D:C09 of A.T.C.C. Deposit Number 207068. SD ¶ 11. Dr. Somerville opines that such a deposit is an example of a polynucleotide containing SEQ ID NO:253 having flanking sequences and as being fully representative of large polynucleotides that can serve as probes or starting materials for probes in cancer diagnostics. SD ¶ 18.

According to Dr. Somerville, the Skilled Person would readily appreciate from the '648 specification that the sequence of SEQ ID NO:253 can be incorporated within a vast number of

larger polynucleotides, and that each of these sequences is identifiable as having at least 50 contiguous nucleotides of SEQ ID NO:253. SD ¶ 17.

The '648 specification contains explicit written support for each of the nucleic acid molecules recited in the claims of each of groups I- and II. This support demonstrates that the inventors describe these nucleic acid molecules, thus satisfying the traditional test for written description articulated in *Vas-Cath*.

The Somerville Declaration, together with its underlying factual support, clearly demonstrates that the '648 specification would have conveyed to one of skill in the art that Appellants possessed the invention of claims 146-154 when the '648 specification was filed. The *Vas-Cath* test is satisfied.

b. Lilly

The factual record in this application also demonstrates that the '648 specification meets both of the tests for an adequate written description of a genus of nucleic acids set forth in *Lilly*. According to *Lilly*, adequate written description of a genus of nucleic acid molecules may be achieved by sufficiently describing a representative number of species within the genus either by defining their nucleotide sequence or by reciting "structural features common to the members of the genus, which features constitute a substantial portion of the genus." 119 F.3d at 1569, 43 U.S.P.Q.2d (BNA) at 1406. The description must permit one of skill in the art to "visualize or recognize members of the genus." 119 F.3d at 1559, 43 U.S.P.Q.2d (BNA) at 1406.

When read in conjunction with the '648 specification, it is Dr. Somerville's unequivocal opinion that, a Skilled Person would find that the '648 specification describes polynucleotides fully representative of the genus of polynucleotides of the Invention since:

- a) the Skilled Person would recognize disclosure of SEQ ID NO:253 as fully representative of the genus of the Invention since it is a complete disclosure of the common structural feature (i.e., at least 50 contiguous nucleotides of SEQ ID NO:253) of the Inventions; and
- b) the Skilled Person would recognize the vector containing a cDNA insert containing the sequence of SEQ ID NO:253 and deposited with the A.T.C.C. is an example of a polynucleotide containing SEQ ID NO:253 and having flanking sequences, and would recognize that the vector is representative of a genus of large polynucleotides that can serve as probes or starting materials for probes in cancer diagnostics. SD ¶ 18.

As discussed above, Dr. Somerville states that the specification provides an explicit description of the common structural feature of each of the claimed genera of nucleic acids, *i.e.*, the polynucleotide sequence of SEQ ID NO:253. SD ¶ 11. Dr. Somerville states that a description of polynucleotides containing at least 50 contiguous nucleotides of SEQ ID NO:253 is found on page 9, lines 6-10 of the '648 specification. SD ¶ 11. Dr. Somerville states that a Skilled Person, taking these disclosures together, would find specific description in the '648 application of the recited common structural feature for Group I claims: the sequence of at least 50 contiguous nucleotides of SEQ ID NO:253. SD ¶ 11.

Dr. Somerville states that the deposited vector that comprises the sequence set forth in SEQ ID NO:253 is fully representative of larger polynucleotides that can serve as probes or starting materials for probes. SD ¶ 18.

The '648 specification, therefore, clearly sets forth the structural feature of the claimed genera. The '648 specification also clearly describes a representative number of species within the species. Both of the tests set forth in *Lilly* are therefore satisfied.

Notably, based on the disclosure of the '648 specification, the Skilled Person would have been able to straightforwardly determine whether a given polynucleotide falls within any one of the claims. SD ¶¶ 45, 20, 27, 31, 41.

c. Enzo

The factual record in this application also demonstrates that the '648 specification meets the tests for written description of nucleic acids articulated in *Enzo*. According to *Enzo*, "the language of the specification, to the extent possible, must describe the claimed invention so that one skilled in the art can recognize what is claimed." 296 F.3d at 1327, 63 U.S.P.Q.2d (BNA) at 1615. Again, the Somerville Declaration establishes that the '648 specification provides sufficient distinguishing information to permit one skilled in the art recognize the identity of the claimed subject matter.

The claims of Group I recite the distinguishing feature of at least 50 contiguous nucleotides of a sequence selected from SEQ ID NO:253. Such is sufficient to describe the claimed invention so that the skilled artisan can recognize what is claimed.

The claim of Group II has the distinguishing feature of at least 50 contiguous nucleotides of an insert in a deposited vector. This feature is sufficient to describe the claimed invention so that the skilled artisan can recognize what is claimed. *Enzo* explicitly approved the use of a deposit to satisfy the written description requirement for a nucleic acid invention:

we hold that reference in the specification to a deposit in a public depository, which makes its contents accessible to the public when it is not otherwise available in written form, constitutes an adequate description of the deposited

material sufficient to comply with the written description requirement of § 112, ¶ 1.”  
*Enzo*, 296 F.3d at 1325, 63 U.S.P.Q.2d (BNA) at 1613.

The Somerville Declaration, together with its underlying factual support, clearly demonstrates that the ‘648 specification would have conveyed to one of skill in the art sufficient distinguishing information to permit one skilled in the art to visualize or recognize the identity of the claimed subject matter. The *Enzo* test is satisfied.

### 3. Specific assertions of the Examiner

#### *The Examiner’s arguments*

The Examiner insists that the appealed claims are not sufficiently described to meet the requirements of 35 U.S.C. § 112, ¶1. This conclusion is based on a single assertion: since the claims are written in open form and, as a consequence, encompass a full length cDNA which is not described in the application, the claims are not adequately described by the specification. The following are exemplary statements by the Examiner during prosecution:

1. “However, claims 22-111 are directed to full length cDNA.....” Paper no. 12, page 7, ¶ 7.
2. “The rejections under 35 USC 112, first paragraph is maintained because a full open reading frame is not described that is related to the claimed invention and therefore the claims (including newly filed claims 132-145) read on undescribed full open reading frames and their encoded polypeptides due to the presence of open language (consisting of) in all claims. Paper no 27 page 2.
3. “However the pending claims continue to read on an unknowable number of species of different polynucleotides that comprise different lengths of undescribed flanking sequences of the full-length cDNA to which SEQ ID NO:253 corresponds. Because newly filed claims 146-154 contain open language that reads on polynucleotides that comprise undescribed flanking sequences of the cDNA to which SEQ ID NO:253 corresponds the rejection for lack of written description has been maintained. Paper no. 32, text bridging pages 3 and 4



Appellants partially agree with the Examiner in the latter two assertions, and have acknowledged throughout prosecution that the claimed genera of polynucleotides encompass full length cDNA.<sup>1</sup> See, e.g., Amendment and Response filed November 1, 2002, page 8 and page 10. Appellants acknowledge that the '648 specification does not specifically describe the sequence of a full length cDNA (although the described sequences do have important utilities that the inventors recognized).

As explained in section I.D.1, *supra*, the claims do not require the claimed molecules be full length cDNA. As far as this record shows, no sequence of a polynucleotide containing more than 50 contiguous nucleotides of SEQ ID NO:253 or complement thereof, including the full-length cDNA, was in the art when Appellants filed the '648 specification. Thus, according to this record, nucleic acid molecules corresponding to the full-length cDNA and comprising more than 50 contiguous nucleotides of SEQ ID NO:253 or a complement thereof, are later-invented species of Appellants' generic invention.

The description of later-discovered species is not required to provide an adequate description of an earlier-discovered genus: "Our case law is clear that an applicant is not required to describe in the specification every conceivable and possible future embodiment of his invention." *Rexnord Corporation v. Laitram Corporation*, 274 F.3d 1336, 1344, 60 U.S.P.Q.2d (BNA) 1851, 1856 (Fed. Cir. 2001). See also *In re Hogan and Banks*, 559 F.2d 595, 605-06, 194 U.S.P.Q. (BNA) 527, 537 (C.C.P.A. 1977); *United States Steel Corporation v. Phillips Petroleum Company*, 865 F.2d 1247, 1251-52, 9 U.S.P.Q.2d (BNA) 1461, 1465 (Fed. Cir. 1989). It is irrelevant whether a later-discovered subgenus consists of only one molecule or, as the Examiner alleges, "an unknowable number of species of different polynucleotides that comprise

---

<sup>1</sup> By "full-length" cDNA, the Office apparently means a cDNA that encodes a "complete open

different lengths of undescribed flanking sequences of the full-length cDNA to which SEQ ID NO:253 corresponds” Paper no 27, page 2. There is simply no basis in the law for the proposition that a genus which is adequately described in a specification as of the filing date nevertheless fails to meet the written description requirement because it is later shown to encompass even a large number of later-discovered species.

Nor is there any basis, either in the law or in this record, for assigning any particular importance to the later-discovered species of full length cDNA containing 50 contiguous nucleotides of SEQ ID NO:253 as part of assessing compliance with the written description requirement. The Examiner’s first assertion -- “However, claims 22-111 are directed to full length cDNA.....” Paper no. 12, ¶ 7. -- is not true. While the claims encompass a genus that includes the full-length cDNA, the claims are not so limited to this species. To say the claims are directed to full length cDNA is a baseless assertion that finds no support in the claims, the specification, or the record. In fact, the essential or critical element of Appellants’ claims is 50 contiguous nucleotides of SEQ ID NO:253 or its complement. The Examiner has cited no basis in the law (nor are Appellants aware of any basis) for the proposition that a genus that is described in the specification fails to meet the written description requirement because one species, even a later-discovered, even preferred, species, is not disclosed. If the Examiner’s rationale were correct, a claim to a chemical process limited to a disclosed temperature range of 0 to 100 degrees would not meet the written description requirement if there was an undisclosed later-discovered optimum temperature range of 50-60 degrees, which falls within that range. Such a conclusion would be contrary to decades of § 112 law.

---

reading frame,” which would encode a complete gene product.

In fact, the factual record of the present application establishes that the inventors specifically describes a wide variety of polynucleotide molecules containing at least 50 contiguous nucleotides of SEQ ID NO:253 along with flanking sequences, e.g. probes, vectors, cDNAs, clones, full length cDNAs, genes etc. SD ¶ 17. Neither the facts of this record nor the law provides the Examiner with a basis for viewing a later-discovered species, having a sequence that is not specifically recited in the claims, as a written description-defeating species of Appellants' earlier-invented genus.

Appellants have presented evidence to contradict the Examiner's assertions, have repeatedly questioned the support underlying the Examiner's rejection and have requested an Examiner's affidavit under 37 C.F.R. § 1.104(d)(2). See Response to October 21, 2001, Office Action filed November 1, 2002, page 7, first full paragraph. Under the case law and its own rules of practice, the Examiner is required to consider the factual evidence in the record, including the Somerville Declaration and its factual underpinnings, and either accept them as true or rebut them with a factual showing of its own. *In re Alton*, 76 F.3d 1168, 1175, 37 U.S.P.Q.2d (BNA) 1578, 1583 (Fed. Cir. 1996). In direct violation of this mandate, the Examiner has dismissed the evidence provided in the Somerville Declaration, including the supporting evidence provided as exhibits:

Neither the applicants response nor the Declaration of Christopher R. Somerville provide reasons why such undescribed flanking sequences are in compliance with the written description requirements of 35 U.S.C. § 112, first paragraph. Paper no. 32 page 4.

The Examiner charges Dr. Somerville fails to provide reasons why flanking sequence are in compliance with the written description requirements of 35 U.S.C. § 112, ¶1.

However, in the same paragraph, the Examiner acknowledges vector polynucleotides that could be flanking sequences are well known to one of skill in the art:

“The applicants arguments, and the arguments of the Declaration of Christopher R. Somerville focus on description of flanking vector sequences that might be linked to SEQ ID NO:253. It is conceded that the structure of such vector sequences are well known to one of skill in the art.” Paper no. 32 page 4.

That said, the Appellants reason that since a large genus of vector flanking sequences are well known, and the sequence of SEQ ID NO:253 is provided in the ‘648 specification, a claim that recites a polynucleotide vector comprising 50 contiguous nucleotides of SEQ ID NO:253 should meet the written description requirements of 35 U.S.C. § 112, ¶1. However, claim 147, which recites a vector comprising 50 contiguous nucleotides of SEQ ID NO:253 or complement thereof, remains rejected.

Because the Examiner has refused Appellants’ request for supporting evidence, the Board may not accept as fact any of the challenged statements of the Examiner. *Application of Lundberg*, 244 F.2d 543, 551, 113 U.S.P.Q. (BNA) 530, 537 (C.C.P.A. 1957). The factual record of this prosecution overwhelmingly establishes that the teachings of the ‘648 specification provide a sufficient written description of the subject matter of appealed claims 146-154.

*The case law cited by the Examiner*

The Examiner has cited *University of California v. Eli Lilly and Co*, *Fiers v. Sugano*, 984 F.2d 1164, 25 U.S.P.Q.2d (BNA) 1601 (Fed. Cir. 1993), *Amgen Inc. v. Chugai Pharmaceutical Co.*, 927 F.2d 1200, 18 U.S.P.Q.2d (BNA) 1016 (Fed. Cir. 1991), *Fiddes v. Baird* 30 U.S.P.Q.2d 1481 (Bd. of Appeals 1993) in support of the written description rejection of the appealed claims. None of this case law supports the rejection of the appealed claims.

Before each of these cases is addressed in turn, the Appellants note that the disputed patents in the above cases were filed between the late 1970s and the mid-1980s. The field of recombinant DNA technology is rapidly evolving, and most major technological advances have been made in the last 20 years. SP ¶ 47. A Skilled Person had a dramatically higher skill level in March 2000 as compared to the filing dates disputed in the above cases. *Id.* Dr. Somerville does not believe that a statement regarding what one of ordinary skill can or cannot do in the above cases could be used as evidence with respect to what the Skilled Person in March of 2000 could or could not do. *Id.* As such, each of the above cases can not be used to support these rejections for two reasons: Firstly, the cases are simply misapplied. Secondly, the decisions in these cases turn on what one of skill in the art could or could not do at the time of filing approximately 20 years ago, which, as we have established, is dramatically different to what one of skill in the art could or could not do in March 2000.

#### Lilly

The Examiner misapplies *Lilly*. The patents at issue in *Lilly* claimed recombinant plasmids containing a subsequence having the structure of the reverse transcript of an mRNA of a vertebrate, which mRNA encodes insulin. The patent specification, however, disclosed a cDNA sequence only for rat insulin, but not for the human or any other vertebrate. The only defining feature recited in the claims of *Lilly* was that the sequence encoded insulin. The Federal Circuit found that recitation of a function of the sequence was not adequate; rather, the specification must provide a structure. Specifically the court stated:

a generic statement such as "vertebrate insulin cDNA" or "mammalian insulin cDNA," without more, is not an adequate written description of the genus because it does not distinguish the claimed genus from others, except by function. It does not specifically define any of the genes that fall within its definition. It does not define any structural features commonly possessed by members of the genus that distinguish them from others. One skilled in the art therefore cannot, as one can

do with a fully described genus, visualize or recognize the identity of the members of the genus. A definition by function, as we have previously indicated, does not suffice to define the genus because it is only an indication of what the gene does, rather than what it is.

*Lilly*, 119 F.3d at 1568, 43 U.S.P.Q.2d (BNA) at 1406 (citations omitted).

The Federal Circuit concluded that only those claims limited to the rat cDNA were valid, and found the generic claim and claims directed to the human insulin-encoding cDNA were invalid as not being adequately described under 35 U.S.C. §112, ¶1. 119 F.3d at 1562-63, 43 U.S.P.Q.2d (BNA) at 1401. of the members of the genus.” 119 F.3d at 1568, 43 U.S.P.Q.2d (BNA) at 1406.

Appealed claims 146-154 differ notably from those at issue in *Lilly* in that each appealed claim particularly recites a specific nucleotide sequence. Only molecules containing such a sequence are literally embraced by the claims, and molecules not containing such a sequence are not. The skilled worker can easily make this determination. SD ¶ 45. In direct contrast, claims of U.S. Patent 4,625,525 at issue in *Lilly* did not recite any particular sequence and merely recited, for example, “a subsequence having the structure of the reverse transcript of an mRNA . . . which mRNA encodes insulin.” *Lilly*, 119 F.3d at 1563, 43 U.S.P.Q.2d (BNA) at 1401. Thus, in contrast to the claims at issue in *Lilly*, the appealed claims do not rely solely upon a function of the claimed polynucleotides, but rather recite structural characteristics, *i.e.*, at least 50 contiguous nucleotides selected from SEQ ID NO:253 or complement thereof (Group I claims) or at least 50 contiguous nucleotides of either strand of nucleotide sequence of an inserted contained in a deposited vector (Group II claim).

Each of claims 146-154 is structurally limited and specifies a particular polynucleotide sequence that a nucleic acid molecule must encode to fall within the scope of the claim. The ‘648

specification discloses those precise sequences and provides an extensive description of additional nucleic acid molecules comprising those sequences. SD ¶¶ 11, 13-17. Those skilled in the art quite easily “visualize or recognize” whether or not any particular nucleic acid molecule encodes the required amino acid sequence and can quite easily determine whether that nucleic acid molecule is encompassed within a particular claim. Somerville Declaration I, ¶ 29. None of the claims contains any limitation that creates any difficulty in identifying whether a nucleic acid molecule is a member of the genus. Accordingly, *Lilly* supports the patentability of the pending claims. The claims satisfy the written description test as set out in *Lilly*.

*Fiers*

Similarly, the Examiner misapplies *Fiers*. *Fiers* reports an award of priority to Sugano in a three-way interference proceeding between Revel, Sugano, and Fiers. 984 F.2d at 1166, 25 U.S.P.Q.2d (BNA) at 1602. In this case, the Federal Circuit applied the holding in *Amgen* to an interference case where three parties (Fiers, Revel, and Sugano) claimed patent rights to the DNA encoding human fibroblast beta interferon (IFN- $\beta$ ). Fiers asserted priority based on his conception of a method for isolating the IFN- $\beta$  DNA in 1979 or early 1980, coupled with due diligence towards a constructive reduction to practice on April 3, 1980. *Id* Before he isolated the DNA, Fiers had disclosed his method to two American scientists, both of whom submitted affidavits that Fiers’ method would have allowed a person of ordinary skill in the art to isolate the IFN- $\beta$  DNA sequence without undue experimentation. *Id*.

Fiers asserted that the stringent written description requirement set forth in *Amgen* only applied when the disclosed method for isolating a DNA sequence could not easily be carried out by one of ordinary skill in the art. *Id*. at 1169. Fiers also argued that *Amgen* allows conception of a DNA sequence by its method of isolation. *Id*. The Federal Circuit rejected both of these

arguments, stating that Fiers was focusing inappropriately on the issue of enablement rather than written description. *Id.* The court also stated that, before reduction to practice, conception only of a process for making a substance, without a conception of a structural or equivalent definition of that substance, cannot constitute more than conception of the substance claimed as a process (product-by-process claim). *Id.* Conception of a substance claimed *per se*, without reference to a process requires conception of its structure, name, formula, or definitive chemical or physical properties. *Id.*

The appealed claims recite a structural definition of the claimed Invention -- at least 50 contiguous nucleotides selected from SEQ ID NO:253 or complement thereof (Group I claims) or at least 50 contiguous nucleotides of either strand of nucleotide sequence of an inserted contained in a deposited vector (Group II claim). Further, the specification provides an extensive description of larger molecules comprising those sequences. SD ¶¶ 11, 13-17. The '648 application therefore meets the standard set out in *Fiers*. *Fiers*, therefore, cannot be used to assert that the subject matter of the appealed claims are not adequately described in the '648 specification. Instead, since the '648 application meets the conception test provided by *Fiers*, *Fiers* may be used in *support* of an assertion that the subject matter of the appealed claims are adequately described in the '648 specification.

*Fiddes v. Baird*

In making the rejection, the Examiner also relied on the 1993 decision in *Fiddes v. Baird*, 30 U.S.P.Q.2d 1481 (Bd. App. Pat. Inf. 1993) in which the Board cited *Fiers* in a priority contest over inventorship of recombinant DNA molecules encoding fibroblast growth factors ("FGFs"). Baird claimed priority on the basis of an application that set forth the amino acid sequence for bovine pituitary FGF and a *theoretical* DNA sequence encoding that protein, along with a



method for obtaining a cDNA corresponding to the protein. The application did not teach the actual naturally-occurring DNA sequence encoding the FGF protein. *Id.* at 1482-81. Since the actual nucleotide sequence of the naturally-occurring DNA molecule was not disclosed, the Board followed *Fiers* in determining that Baird was not in possession of the broad class of naturally-occurring genes encoding mammalian FGFs:

An adequate description of a DNA requires more than a mere statement that it is part of the invention and reference to a potential method for isolating it; what is required is a description of the DNA itself.

\* \* \*

If a conception of a DNA requires a specific definition, such as by structure, formula, chemical name, or physical properties, as we have held, then a description also requires that degree of specificity....[O]ne cannot describe what one has not conceived. *Id.* at 1482-83, citing *Fiers*, 984 F.2d at 1170-71.

In contrast, the appealed claims are not directed to theoretical molecules that the Appellants hope to be able to obtain by a disclosed method. The appealed claims are directed to molecules comprising specific sequences that Appellants actually obtained. The '648 specification discloses those precise sequences and provides an extensive description of additional nucleic acid molecules comprising those sequences. SD ¶¶ 11, 13-17. *Fiddes v. Baird*, therefore, cannot be used to assert that the subject matter of the appealed claims are not adequately described in the '648 specification. Instead, since the '648 application meets the conception test provided by *Fiddes v. Baird*, *Fiddes v. Baird* may be used in support of an assertion that the subject matter of the appealed claims are adequately described in the '648 specification.

Amgen, Inc. v. Chugai Pharmaceutical, Co.

In *Amgen, Inc. v. Chugai Pharmaceutical*, 927 F.2d 1200, 18 U.S.P.Q.2d (BNA) 1016 (Fed. Cir. 1991), *Co.*, the Federal Circuit considered an Amgen patent issued on October 27, 1987, which contained claims to the DNA sequence encoding human erythropoietin (EPO). Amgen claimed priority of invention based on isolation of EPO clones in 1983.

Prior to Amgen's cloning of the EPO gene, however, Genetics Institute ("GI") had isolated and purified the EPO protein, and had also disclosed a strategy for obtaining the EPO DNA sequence. *Id.* at 1205. The USPTO issued a patent to GI on June 30, 1987 with claims to the EPO protein itself. *Id.* at 1203. GI did not actually clone the EPO cDNA until August 1984, and began making recombinant EPO using the cDNA shortly thereafter. *Id.* at 1205-06.

The Federal Circuit held that the Amgen patent was not invalidated by GI's earlier-disclosed isolation strategy to obtain the EPO DNA and its sequence, even though this strategy eventually resulted in the actual cloning of the gene by GI. *Id.* at 1206. GI's disclosure of the protein, and a method for isolating and purifying the EPO DNA sequence, was insufficient to constitute actual conception of the DNA encoding EPO. *Id.* Applying chemical case law precedent,<sup>2</sup> the Amgen court stated:

A gene is a chemical compound, albeit a complex one, and it is well established in our law that conception of a chemical compound requires that the inventor be able to define it so as to distinguish it from other materials, and to describe how to obtain it. Conception does not occur unless one has a mental picture of the structure of the chemical, or is able to define it by its method of preparation, its physical or chemical properties, or whatever characteristics sufficiently distinguish it. It is not sufficient to define it solely by its principle biological property, *e.g.*, encoding human erythropoietin, because an alleged conception having no more specificity than that is simply a wish to know the identity of any

---

<sup>2</sup> See *Oka v. Youssefye*, 849 F.2d 581, 583 (Fed. Cir. 1988). The court, in *Amgen*, classified DNA as a complex chemical compound and held that "it is well established in our law that conception of a chemical compound requires that the inventor be able to define it so as to distinguish it from other materials, and ... describe how to obtain it." *Amgen*, 927 F.2d at 1206.

material with that biological property. *Amgen v. Chugai Pharmaceuticals*, 927 F.2d at 1206 (citations omitted)

Thus, since GI had not yet cloned the DNA sequence encoding EPO when it filed its patent application, and the specification only suggested a possible method by which to isolate the DNA sequence, GI could not have a mental conception of the EPO DNA sequence at the time the application was filed. *Id.* The court did not invoke the requirement that the actual DNA sequence be disclosed, but only that the DNA be defined in a way to distinguish it from other chemicals along with a description of how to obtain it. *Id.*

In contrast, the appealed claims are not directed to theoretical molecules that the Appellants hope to be able to obtain by a disclosed method. The appealed claims are directed to molecules comprising specific sequences that Appellants actually obtained. The '648 specification discloses those precise sequences and provides an extensive description of additional nucleic acid molecules comprising those sequences. SD ¶¶ 11, 13-17. *Amgen*, therefore, cannot be properly applied to assert that the subject matter of the appealed claims are not adequately described in the '648 specification. Instead, since the appealed claims recite a structure that is fully described in the '648 specification SD ¶¶ 11, 13-17, the application actually passes the tests provided by *Amgen*.

*The Facts of the Cited Cases are Distinct from those of the Instant Application*

None of the cases cited in support of the written description rejection of claims 146-154 provide a situation analogous to the one at hand. In each of the cited cases, a party was attempting to broadly claim a DNA sequence based on its function (e.g., as in *Lilly*, which relied upon the function of the cDNA in encoding insulin) or where no sequence is described, but rather only a method for obtaining it (e.g., as in *Fiers* and *Fiddes*).

None of the cited cases consider a situation where the specification described a sequence present in all members of the claimed genus of sequences, or other structural characteristic common to all members of the claimed genus. Further, without such a common structural characteristic, the court found in each case that the specification did not describe the claimed polynucleotides "so as to distinguish it from other materials." In contrast, the appealed claims do provide such a common structural feature. As such, the facts of the cited cases are not analogous to those of the instant case; in fact, the reasoning set out in the cited cases actually support a finding that the appealed claims are adequately described by the instant application.

As stated in *Amgen*, DNA is simply a chemical compound that can be conceived of by a mental picture of the structure of the compound or whatever characteristics sufficiently distinguish it. In *Lilly*, the court stated that in claims involving chemical materials, generic formulae must indicate with specificity what the claims encompass such that one skilled in the art can distinguish the formula from other formulas and can identify many of the species the claims encompass. Such a formula generally constitutes an adequate written description of the claimed genus. *Lilly* also held that a description of a genus of cDNAs may be achieved by recitation of structural features common to the members of the genus. Moreover, the court in *Fiers* held that conception of a substance requires conception of its structure, formula, or definitive chemical or physical properties.

In the instant application, the claims recite an element – either a particular nucleotide sequence or an insert of a deposited vector -- that provides a distinguishing feature common to the genus of claimed polynucleotides. The recited element provides a structural feature common to all the members of the claimed genera, serves to define the claimed genus. With the knowledge of the nucleotide sequence of SEQ ID NO: 253 and with the availability of the insert

of the deposited vector, one skilled in the art can easily determine if a sequence is a member of the claimed genus.

Each of the appealed claims recite a critical defining feature – one that was said to be lacking in the claims considered and rejected in each of *Amgen*, *Fiers*, *Lilly*, and *Fiddes*. The feature of the claims defines the claimed polynucleotide “so as to distinguish it from other materials.” *Amgen vs. Chugai*, 927 F.2d at 1206. The recited sequence also provides “a structural or equivalent definition” of the claimed polynucleotide. *Fiers*, 984 F.2d at 1169. *See also Fiddes*, 30 U.S.P.Q.2d at 1482-83. Moreover, the sequence recited in the claims provides “a recitation of structural features common to the members of the [claimed] genus.” *Lilly*, 119 F.3d at 1568-69. Thus, it is much more than a mere wish to obtain a composition – it defines the composition.

4. Appellants’ use of the term “comprising” is entirely proper

In contrast to the Examiner’s position, the present application presents a strong case for issuing open-ended claims.

The appealed claims are based on the inventors’ discovery of polynucleotides, which are defined in the claims as containing at least 50 contiguous nucleotides selected from SEQ ID NO:253 or having at least 50 contiguous nucleotides of either strand of a nucleotide sequence of an insert contained in a deposited vector. The claimed polynucleotides may be used to detect polynucleotides that are expressed at higher levels in cancerous cells as compared to non-cancerous cells. The sequence of SEQ ID NO:253 is provided in the ‘648 specification, and provides an extensive description of additional nucleic acid molecules comprising those sequences. SD ¶¶ 11, 13-17. The claimed polynucleotides may serve as probes or starting materials for probes in cancer diagnostics. SD ¶ 18. There is no criticality to sequences flanking the claimed polynucleotides. SD ¶ 17. Rather, selection of such flanking sequences is an

arbitrary matter of design. *Id.* The Skilled Person would readily appreciate from the specification that the sequence of SEQ ID NO:253 can be incorporated within a vast number of larger polynucleotides, and that each of these sequences is identifiable as having at least 50 contiguous nucleotides of SEQ ID NO:253. *Id.*

The present application, therefore, is simply not a case in which Appellants are attempting to claim DNA fragments in open language without knowing the identity or function of the gene to which the fragments belong, or where the fragments have no demonstrated or medically important utility. Any polynucleotide containing 50 contiguous nucleotides of SEQ ID NO:253, no matter how large the polynucleotide, has a utility as a diagnostic probe for cancer, or a starting material for such a probe. SD ¶ 18.

The U.S. Patent and Trademark Office routinely issues patents that claim DNA molecules encoding full-length genes using open language, as indicated by numerous issued patents. The Office should not find anything per se objectionable about open-ended nucleic acid claims, regardless of whether the claim-recited nucleic acid is a fragment of a so-called “full-length” cDNA. There is no reasonable basis under the guise of the written description requirement or any other portion of the patent laws for allowing open-ended claims if the recited sequence is “full-length” while denying open-ended claims solely because the claims are defined by a recited sequence that is only a portion of a “full-length” cDNA. To the extent the Office has applied this distinction in this case, it is an arbitrary distinction unfounded in the law, and it should be disregarded.

There is good reason for allowing open-ended claims to useful polynucleotide molecules like those invented by Appellants. In the recombinant nucleic acid field, making and using specific polynucleotide molecules routinely involves incorporating the specific polynucleotides

into larger molecules, including cloning and expression vectors. Specific polynucleotide molecules retain their essential utility when linked to additional sequences. Obviously, the variety of useful larger molecules comprising a specific polynucleotide sequence is essentially limitless. In the recombinant DNA field, the practical reality is that larger polynucleotide molecules into which the inventive polynucleotide molecule can be inserted should be viewed simply as the functional milieu in which an inventive sequence can be made and used. In this context, inventors of polynucleotides would be deprived of meaningful patent protection if claims were limited by closed language to the inventive polynucleotide or to specific larger molecules into which Appellants actually incorporated the inventive polynucleotide molecule. Others could use the inventions but avoid the claims easily merely by using the inventive sequences in unclaimed larger molecules. Closed claims for nucleic acids would utterly eviscerate patent protection for those inventions.

These concerns apply unequivocally to Appellants' claims. The closed claims offered by the Examiner would not provide Appellants with patent protection commensurate with their invention. The record shows that Appellants specifically teach, and the skilled worker was well aware, that the inventive sequences should be incorporated into larger molecules to make and use them. The record shows that closed claims would deprive Appellants of patent protection on polynucleotides that are fully described in the specification, a representative example of which is deposited at the A.T.C.C. See Somerville Declaration at ¶¶ 11-18. A polynucleotide containing an addition of a few nucleotide bases or even a single nucleotide base to the end of the recited polynucleotide sequence would retain the utility of the disclosed molecules and yet be outside of the scope of such closed-ended claims. In short, denying Appellants the open-ended claims

would permit anyone to avoid Appellants' claims while taking full advantage of Appellants' contribution to the art.

The U.S. patent system was not designed to provide such meaningless protection, and the Office does not achieve the constitutional purpose of the patent system when it attempts to force patentees to accept claims of literally no value. As the Court of Customs and Patent Appeals has stated:

The public purpose on which the patent law rests requires the granting of claims commensurate in scope with the invention disclosed. This requires as much the granting of broad claims on broad inventions as it does the granting of more specific claims on more specific inventions. It is neither contemplated by the public purpose of the patent laws nor required by the statute that an inventor shall be forced to accept claims narrower than his invention in order to secure allowance of his patent. It is, however, consistent with this public purpose embodied in the pertinent statutory requirement that the *invention claimed* shall be no broader than the *invention set forth* in the written description forming part of the specification.

*In re Sus and Schaefer*, 306 F.2d 494, 497, 134 U.S.P.Q. (BNA) 301, 304 (C.C.P.A., 1962), emphasis in original.

Open claims to inventive nucleic acid sequences are analogous to open claims in other fields. For example, claims are routinely allowed that encompass all pharmaceutical formulations of an inventive pharmaceutical without any limitation on the type of pharmaceutical formulation. Where the invention is in the agent, there is no justification for restricting the type of formulation in which the agent could be included, even though such claims would read on future discovered formulations that contain the agent and even where all possible formulations are not described in the application.

The clear rationale for permitting applicants to claim pharmaceutical formulations comprising patentable agents using open-ended language is that requiring any claim limitation on



a collateral feature (such as the specific formulation) would allow competitors to use the invention simply by altering a nonessential collateral feature. The law does not limit the inventor of a new pharmaceutical agent to claims covering only the agent itself or the specific formulations the inventor actually made.

In other words, there is no way for Appellants to obtain claims commensurate with Appellants' invention of new and useful sequences other than to claim nucleic acid molecules comprising those sequences. Closed claims like those that would likely satisfy the Examiner (e.g., directed to a "polynucleotide consisting of at least 50 contiguous nucleotides of SEQ ID NO:253") would be no more useful or fair than a claim to "a device consisting of [an inventive valve]" that could not be enforced against a manufacturer or user of a larger device comprising the valve or a claim to a "new pharmaceutical agent" that could not be enforced against a manufacturer who incorporated the agent into a formulation for administration.<sup>3</sup>

The Examiner has relied on its core objection that the appealed claims encompass molecules that are larger than at least 50 contiguous polynucleotides of SEQ ID NO:253 that could include full length cDNA, and that the sequence of this full length cDNA is not specifically described in the specification. In other words, the Examiner is reading a limitation in

---

<sup>3</sup> Not only does the law provide no justification for imposing unique patentability requirements on inventions of useful nucleic acid sequences, the law actually proscribes any such differential treatment. Article 27.1 of the TRIPS Agreement states in part that "patents shall be available and patent rights enjoyable without discrimination as to the place of invention, the field of technology and whether products are imported or locally produced." Agreement on Trade-Related Aspects of Intellectual Property Rights, April 15, 1994, Marrakech Agreement Establishing the World Trade Organization, Annex 1C, Legal Instruments – Results of the Uruguay Round, 33 I.L.M. 81 (1994). If the United States, through TRIPS, forces the rest of the world to comply with western-style intellectual property norms, we ourselves should not treat any particular technology differently than all other technologies. The uniquely heightened written description standard that the U.S. Patent and Trademark Office seems to be applying to nucleic acid inventions in this case would violate this portion of Article 27.1.

to the claim which is simply not present: the sequence of the full length cDNA corresponding to SEQ ID NO:253.

The sequence of the full length cDNA corresponding to SEQ ID NO:253 is not taught in the '648 application, is not specifically recited in the claims and, as a point of fact, would represent later-discovered species within those claims. These later-discovered species may have new uses not possessed by all molecules claimed by Appellants, and in fact they may be patentable over Appellants' claims. But no case has ever held that the later development of a separately patentable species renders a prior genus unpatentable. No case has ever questioned that later-invented species may be dominated by earlier generic inventions -- in fact that situation is commonly the case and is understood in the law to be normal in fast-evolving arts. There is no uniquely-applicable basis in law or science for deeming generic nucleic acid sequence patents meeting the statutory requirements of patentability inappropriate simply because they dominate any later-discovered full length genes. Such a special, hindsight-based evaluation of generic nucleic acid claims would not only be contrary to fundamental principles of patent law, but in the long run would surely undermine the nucleic acid art. Thus, the Examiner's objection is baseless, does not respond to the legal or policy issues raised by Appellants, and should be disregarded.

E. Conclusion

Appellants have provided the U.S. Patent and Trademark Office with an extensive factual record which establishes without question that all the claims of groups I and II (claims 146-154), each of which should be separately analyzed, meet the written description requirement of 35 U.S.C. § 112, ¶1. There is no evidence in the record to the contrary. The evidentiary record establishes that the '648 specification conveys to one of skill in the art that Appellants possessed

the invention to which the appealed claims are directed when that specification was filed. *Vas-Cath*, 935 F.2d at 1563-64, 19 U.S.P.Q.2d (BNA) at 1117. The evidentiary record establishes that the '648 specification describes the claimed invention so that one skilled in the art can recognize what is claimed. *Enzo*, 296 F.3d at 1327, 63 U.S.P.Q.2d (BNA) at 1615. The evidentiary record establishes that the '648 specification sufficiently described a representative number of species within each recited genus of polynucleotide molecules to permit one of skill in the art to "visualize or recognize members of the genus." *Lilly*, 119 F.3d at 1559, 43 U.S.P.Q.2d (BNA) at 1406.

In making the written description rejection, the Examiner has ignored the full extent of the evidentiary record and has improperly focused on unrecited features defining species of full length cDNA. The sequence of the full-length cDNA is not specifically recited in the claims or essential to Appellants' invention. It would be a later-discovered species of the generic invention embraced by appealed claims 146-154. The '648 specification need not have described them.

The rejection should be reversed.

#### **REQUEST FOR ORAL HEARING**

Appellants request an oral hearing on this appeal, and enclose two additional copies of this Brief in connection therewith.

CONCLUSION

For the reasons given above, the rejection of claims 146-154 under 35 U.S.C. § 112, ¶1 is improper. The Board of Patent Appeals and Interferences should reverse the rejection.

Respectfully submitted,  
BOZICEVIC, FIELD & FRANCIS LLP

Date: Dec 11, 2003

By: James S. Keddie  
James S. Keddie  
Registration No. 48,920

Date: Dec 11, 2003

By: Carol L. Francis  
Carol L. Francis  
Registration No. 36,513

BOZICEVIC, FIELD & FRANCIS LLP  
200 Middlefield Road, Suite 200  
Menlo Park, CA 94025  
Telephone: (650) 327-3400  
Facsimile: (650) 327-3231

## APPENDIX 1. APPEALED CLAIMS

146. An isolated polynucleotide comprising at least 50 contiguous nucleotides of a sequence selected from SEQ ID NO:253 and the complement thereof.
147. A vector comprising a polynucleotide of claim 146.
148. A host cell comprising the vector of claim 147.
149. An isolated polynucleotide comprising at least 50 contiguous nucleotides of SEQ ID NO:253 and which hybridizes under stringent conditions to a polynucleotide of a sequence selected from SEQ ID NO:253 and the complement thereof.
150. The polynucleotide of claim 149, wherein hybridization is conducted at least 50°C and using 0.1XSSC (9 mM saline/0.9 mM sodium citrate).
151. A polynucleotide comprising at least 50 contiguous nucleotides of either strand of a nucleotide sequence of an insert contained in a vector deposited as clone number M00001448D:C09 of A.T.C.C. Deposit Number 207068, wherein the insert is a human cDNA and the clone is obtained from a human cDNA library.
152. An isolated polynucleotide comprising at least 50 contiguous nucleotides of SEQ ID NO:253, said polynucleotide obtained by amplifying a fragment of cDNA using at least one polynucleotide primer comprising at least 15 contiguous nucleotides of a nucleotide sequence selected from the group consisting of: SEQ ID NO: 253 and the complement thereof.
153. A vector comprising a polynucleotide of claim 152.
154. A host cell comprising the vector of claim 153.